Costus: Antimicrobial and Antiviral Evidence

Crepe ginger’s antimicrobial literature is broader than most single-herb infection literatures on this site: real minimum inhibitory concentration (MIC) values against fungi and bacteria, one study that went beyond the Petri dish and confirmed activity in infected mice, and two different viruses screened under two different names for the same plant. This page also prints the arithmetic that this site applies to any in-vitro potency claim, and the numbers point somewhere specific — toward the plant’s traditional topical use for skin conditions, not toward drinking it as a systemic anti-infective.

Table of Contents

  1. The Claim
  2. Antibacterial Activity: Species and Zones
  3. Antifungal Activity and the Named Compound
  4. The MIC Gap: Scaling a Petri Dish to a Person
  5. The One Study That Went Further: In Vivo Confirmation
  6. Antiquorum-Sensing Activity, Briefly
  7. Antiviral Screening: Two Different Viruses
  8. Costus speciosus vs Costus pictus
  9. Ethnobotanical Corroboration
  10. Topical Tradition and What the Arithmetic Actually Supports
  11. What a Real Trial Would Measure
  12. Key Research Papers
  13. Connections

The Claim

Crepe ginger rhizome is traditionally used across its range for skin diseases, wounds, and as what several sources describe generally as an “anti-infective agent.” The modern literature testing that claim is a genuine multi-decade, multi-country effort — the earliest citation on this page is from 1988, the most recent from 2026 — spanning antibacterial, antifungal and, more recently, antiviral screening.

Back to Table of Contents

Antibacterial Activity: Species and Zones

Several independent groups have tested rhizome extracts and isolated compounds against standard bacterial panels, with consistent activity reported against both Gram-positive and Gram-negative organisms.

Back to Table of Contents

Antifungal Activity and the Named Compound

The antifungal literature has the oldest and, in some ways, the most precisely characterised result on this page. Bandara and colleagues, in 1988, identified methyl ester of para-coumaric acid as “the antifungal principle of the rhizome of Costus speciosus” — a single-compound identification, in Planta Medica, that has stood as a reference point for 35 years.

Duraipandiyan and colleagues (2012) went further with a different compound, publishing real minimum inhibitory concentrations for costunolide against a panel of dermatophyte fungi:

The compounds did not inhibit any bacteria tested in that study — costunolide and eremanthin were active against fungi only, a genuinely useful negative finding that sharpens rather than dilutes the antifungal claim. Ibrahim and colleagues (2019), continuing the same group’s work, reported further MIC values for a related isolated compound the group named specioic acid: 150 µg/mL against S. aureus, 400 µg/mL against E. coli, 550 µg/mL against B. cereus, and 320 µg/mL against C. albicans.

Back to Table of Contents

The MIC Gap: Scaling a Petri Dish to a Person

This site does not let an in-vitro potency figure stand as if it settled anything about a person taking the plant by mouth — the assumptions get printed and checked, the way they were for savory’s essential oil elsewhere on this site. Costunolide’s MIC data make that arithmetic possible here, and it is worth doing precisely because most herb pages never have real MIC numbers to work with at all.

Take the single most potent value: 31.25 µg/mL against T. rubrum, the fungus behind most nail and skin dermatophyte infections. To reach that concentration systemically, across the roughly 42 litres of total body water in an average adult, before any loss to absorption, first-pass liver metabolism, protein binding or elimination:

31.25 mg/L × 42 L ≈ 1,313 mg (about 1.3 g) of pure, isolated costunolide

That is 1.3 grams of a single purified compound, not crude rhizome — and Duraipandiyan’s own methods make clear costunolide is obtained only after “column chromatography” extraction and purification from the crude hexane extract, meaning it is a minor constituent by weight, not a bulk one. No paper in this literature reports what percentage of dried rhizome costunolide actually represents, so the crude-rhizome-equivalent dose cannot be calculated honestly — only bounded below by the 1.3 g pure-compound figure, and almost certainly several to many multiples higher once diluted back into whole rhizome. That gap is refused rather than guessed at, in line with this site’s standing rule against inventing a number nobody has measured.

The same arithmetic on the antibacterial side is more clear-cut still. Specioic acid’s MIC of 150 µg/mL against S. aureus scales to 150 mg/L × 42 L ≈ 6.3 g of pure isolated compound to reach systemically — nearly five times the fungal figure, for a bacterium that causes ordinary skin and wound infections, not a deep systemic one requiring blood-level dosing in the first place.

Back to Table of Contents

The One Study That Went Further: In Vivo Confirmation

This is the strongest single piece of evidence anywhere across this Benefits set, and it is worth naming why: Petri-dish inhibition is a starting hypothesis, and it is rare for any plant’s antimicrobial literature on this site to include a study that confirms the effect in an actual infected animal. Crepe ginger has one.

Sima and colleagues (2020) prepared Cheilocostus speciosus rhizome extracts in five different solvents and tested them against clinically significant multi-drug-resistant (MDR) isolates: methicillin-resistant Staphylococcus aureus (MRSA), MDR Acinetobacter baumannii, Klebsiella pneumoniae serotype K2, MDR Pseudomonas aeruginosa, Salmonella typhimurium, and MDR E. coli. In vitro, the extract showed a potent bactericidal effect against MRSA and K. pneumoniae K2, and a pronounced bacteriostatic effect against E. coli. The researchers then infected BALB/c mice with K. pneumoniae K2 or MRSA alongside their standard reference strains and treated them with the extract, finding it significantly reduced bacterial load in the mice’s lungs, liver and spleen — and the extracts were more effective against the multi-drug-resistant strains than against the standard reference strains.

This does not establish a human dose, a safe route of administration, or anything about toxicity at an effective dose — the paper is a proof-of-concept for further antibiotic development, explicitly framed that way by its own authors, not a demonstration that crepe ginger treats infection in people. But it is a genuine step beyond a dish, in a real infection model, against real drug-resistant organisms, and it deserves to be reported as such.

Back to Table of Contents

Antiquorum-Sensing Activity, Briefly

Ibrahim and colleagues (2019) also tested their isolated sesquiterpenes against Chromobacterium violaceum’s quorum-sensing system — the chemical communication network bacteria use to coordinate collective behaviours like biofilm formation, at population densities rather than as individual cells. Specioic acid showed a moderate quorum-sensing-inhibitory effect, visible as disappearance of the organism’s characteristic violet pigment. This is a mechanistically distinct claim from direct antibacterial killing — a quorum-sensing inhibitor can theoretically disarm a bacterial population’s coordinated behaviour without killing it outright, a different and, in principle, lower-resistance-risk strategy. It remains a single in-vitro finding with no follow-up confirmation anywhere in this literature.

Back to Table of Contents

Antiviral Screening: Two Different Viruses

Two recent studies have tested this plant against two unrelated viruses, using two different plant parts, and — notably — two different taxonomic names for the same species.

Influenza A H1N1. Senevirathne and colleagues (2023), publishing in Viruses, tested aqueous leaf extract of Costus speciosus against influenza A H1N1, both in cell culture and in an animal model, reporting suppressed viral activity in both settings. This is already covered on the main Costus page and is one of the better-designed studies in this entire literature, because it includes a genuine in-vivo arm rather than stopping at cell culture.

Human adenovirus. Alnhhas and colleagues (2026), publishing in Frontiers in Pharmacology, tested methanolic and ethanolic rhizome extracts of — in their own words — “Hellenia speciosa (J. Koenig) S.R. Dutta [syn. Costus speciosus (J. Koenig) Sm.; Costaceae]” against human adenovirus, using Vero cells for both cytotoxicity and antiviral testing, guided by molecular docking against the viral DNA polymerase. The methanolic extract showed low cytotoxicity and potent antiviral effect; the ethanolic extract also showed notable activity, with a reported favourable selectivity index (the ratio between a toxic dose and an effective dose — a real and relevant safety measure for an in-vitro antiviral result, and one many screening papers omit).

The Hellenia speciosa naming is not a different plant slipping in under a similar name — it is confirmed, in the paper’s own text, as a synonym of this exact species, matching the main Costus page’s own note that older sources use Hellenia speciosa as an alternative binomial. Named here exactly as the paper itself names it, per this site’s standing practice for any species with more than one taxonomic name in circulation.

Two viruses, two plant parts, two research groups, both reporting activity, both entirely in-vitro-and-computational with no human data of any kind. A real and growing antiviral screening literature, still at its earliest stage.

Back to Table of Contents

Costus speciosus vs Costus pictus

One more identity note worth adding to the main page’s four-plant “costus problem.” Shaikh, Bawazir and Yahya’s 2022 antimicrobial study is one of the few papers in this entire literature to test Costus speciosus and Costus pictus side by side, under identical conditions, specifically because the two are confusable in trade. Costus pictus is a separate ornamental spiral ginger, also promoted in parts of India as an “insulin plant” alongside Chamaecostus cuspidatus — a third plant carrying that nickname, on top of the two the main page already documents.

Both species showed real phytochemical content (alkaloids, flavonoids, quinones and saponins in both) and real antibacterial activity against the five-organism panel in this comparative study. The abstract does not break down which species performed better against which specific organism, so this page reports the finding at the level the source actually supports: a rigorous side-by-side comparison confirms both plants are chemically and biologically active, not that one clearly outperforms the other — and its greater value is methodological, as a demonstration that researchers themselves have needed to test these plants together specifically because buyers cannot reliably tell them apart.

Back to Table of Contents

Ethnobotanical Corroboration

Independent of any laboratory assay, a 2014 ethnobotanical field survey by Junsongduang and colleagues, comparing Karen and Lawa medicinal-plant knowledge in two villages in northern Thailand, found Costus speciosus carried the highest cultural importance index of any plant in the Karen village — used specifically to treat urinary infections and wounds in animals. That is a real, independently documented traditional infection-related use, recorded through structured interviews with 67 informants rather than assumed from a compound’s general reputation — though note precisely what it documents: veterinary use, not a human clinical claim, and cultural prominence rather than any tested outcome.

Back to Table of Contents

Topical Tradition and What the Arithmetic Actually Supports

Put the MIC arithmetic and the traditional-use record next to each other and they point the same direction. The main Costus page and Duraipandiyan’s introduction both list skin diseases among this plant’s traditional indications, and Junsongduang’s field survey documents real use on wounds specifically. A topical application — a poultice, paste or wash placed directly on skin, a wound or a fungal nail — only has to reach an effective concentration at the surface it is touching, not throughout 42 litres of body water after surviving digestion, liver metabolism and dilution into the bloodstream. That is a dramatically easier bar to clear than the systemic arithmetic above, and it is the route the tradition itself actually describes.

The honest position, stated plainly: the MIC values in this literature are real and worth taking seriously as a starting point for topical use, exactly where tradition already points. They are not evidence that drinking crepe ginger tea or swallowing a rhizome capsule delivers an antimicrobial dose anywhere in the body — the arithmetic above shows that gap is large, and nobody has measured how much of it a real preparation closes. Marketing that implies an oral, systemic anti-infective effect is reaching well past what this evidence, read honestly, actually supports.

Back to Table of Contents

What a Real Trial Would Measure

Antimicrobial and antiviral effect is not a hard thing to test rigorously — clinical microbiology has standard, validated ways to measure exactly this, and none of them has been applied to crepe ginger in a human infection. Naming the missing measurements precisely is more useful than a general claim that traditional remedies resist proper testing.

  1. For a topical skin or wound application — the route the arithmetic above actually supports — a real trial would report time to wound closure, quantitative bacterial culture from the wound bed before and after treatment, and rate of clinical infection recurrence, against a standard antiseptic or antibiotic ointment comparator.
  2. For the dermatophyte claim specifically — the one costunolide’s own MIC data actually speaks to — mycological cure (a negative fungal culture) and complete cure (negative culture plus resolved symptoms) at a fixed follow-up point, the same endpoints used in every registration trial for a licensed topical antifungal.
  3. For any claim about drinking or eating the plant as an anti-infective, a measured serum or tissue concentration of costunolide or specioic acid after a realistic dose, compared against the MIC values this page already has — the single most direct way to close the gap the arithmetic above leaves open, and the one measurement that would resolve the topical-versus-oral question definitively rather than by inference.
  4. For the antiviral findings, a viral load reduction and time-to-symptom-resolution in an actual respiratory or adenoviral illness, against placebo — the standard design for any antiviral trial, and one that has been run for many other natural compounds but not this one.

Every one of these is a routine clinical-trial endpoint, in continuous use for testing licensed antimicrobial and antiviral products. None has been pointed at crepe ginger. That is a gap in research investment, not evidence the plant cannot be tested properly.

Back to Table of Contents

Key Research Papers

Every citation below was checked against the live PubMed record before being written onto this page, using a title/abstract-scoped, species-locked search to confirm the paper concerns this plant specifically.

  1. Bandara BM, Hewage CM, Karunaratne V, Adikaram NK. Methyl ester of para-coumaric acid: antifungal principle of the rhizome of Costus speciosus. Planta Medica, 1988. — PubMed search
  2. Duraipandiyan V, Al-Harbi NA, Ignacimuthu S, Muthukumar C. Antimicrobial activity of sesquiterpene lactones isolated from traditional medicinal plant, Costus speciosus (Koen ex.Retz.) Sm. BMC Complementary and Alternative Medicine, 2012. Real MIC values for costunolide against dermatophytes. — PubMed search
  3. Al-Attas AA, El-Shaer NS, Mohamed GA, Ibrahim SR, Esmat A. Anti-inflammatory sesquiterpenes from Costus speciosus rhizomes. Journal of Ethnopharmacology, 2015. The isolation work behind the compounds tested for antimicrobial activity below. — PubMed search
  4. Ibrahim SRM, Ahmed El-Shaer NSA, Asfour HZ, et al. Antimicrobial, antiquorum sensing, and antiproliferative activities of sesquiterpenes from Costus speciosus rhizomes. Pakistan Journal of Pharmaceutical Sciences, 2019. Specioic acid MIC values against bacteria and Candida. — PubMed search
  5. Sima Z, Fadwa H, Basem D, Omar G, Ahmed AS. In vitro and in vivo Antibacterial Activity of Cheilocostus speciosus Rhizome Extract on Resistant Bacteria. Pakistan Journal of Biological Sciences, 2020. Confirmed reduced bacterial load in infected mice — the strongest single study in this Benefits set. — PubMed search
  6. Shaikh SS, Bawazir AS, Yahya BA. Phytochemical, Histochemical and In Vitro Antimicrobial Study of Various Solvent Extracts of Costus speciosus (J. Koenig) Sm. and Costus pictus D. Don. Turkish Journal of Pharmaceutical Sciences, 2022. The direct speciosus vs pictus comparison. — PubMed search
  7. Dawod MFM, Abdelwahab SI, Sidahmed H, Taha MME, Elamin AI, Al-Zubairi AS. Comparative evaluation of antimicrobial activities and molecular docking of selected medicinal plants used in Arab countries using zamzam water and conventional solvents. Scientific Reports, 2026. — PubMed search
  8. Senevirathne A, et al. The Aqueous Leaf Extract of the Medicinal Herb Costus speciosus Suppresses Influenza A H1N1 Viral Activity under In Vitro and In Vivo Conditions. Viruses, 2023. — PubMed search
  9. Alnhhas S, et al. Antiviral activity of Hellenia speciosa (J. Koenig) S.R. Dutta rhizome metabolites against human adenovirus: insights from molecular docking and in vitro studies. Frontiers in Pharmacology, 2026. — PubMed search
  10. Junsongduang A, Balslev H, Inta A, Jampeetong A, Wangpakapattanawong P. Karen and Lawa medicinal plant use: uniformity or ethnic divergence? Journal of Ethnopharmacology, 2014. Highest cultural-importance-index plant in the surveyed Karen village, used for urinary infections and animal wounds. — PubMed search

Back to Table of Contents

Connections

Back to Table of Contents